Veea Inc. and NovaGen Group announced a planned merger to create NovaGen Health Networks, a connected health platform co

Veea Inc., a NASDAQ-listed provider of AI-powered, cybersecure edge infrastructure, and NovaGen Group B.V., a personalized regenerative medicine and longevity company, have signed a term sheet to combine their operations. The companies are targeting execution of a definitive business combination agreement within the coming weeks. As part of the deal, they will launch NovaGen Health Networks, a connected health platform that integrates Veea's edge computing, connectivity and cybersecurity capabilities with NovaGen's cellular reprogramming science and clinical services. Initial deployments are planned to begin at NovaGen clinics and partner hospitals in the fourth quarter of 2026.

NovaGen Health Networks is built on VeeaONE, Veea's platform, and will connect health records, wearable and sensor data, and biological measurements into a patient-controlled longitudinal health profile. Local computing supports agentic AI applications close to the patient, with patient-directed permissions governing access to personal data. The rollout will begin with connected health services and expand to clinician-supervised diagnostics and therapy pathways as clinical validation and applicable regulatory authorizations permit.

GeoNova Capital has signed a term sheet as a cornerstone investor to provide an initial investment of US$10 million in the combined company. Management believes that based on internal projections and an independent valuation, the value of the combined company is approximately $750 million. Veea will continue to grow and serve its existing customers, partners and markets. The business combination and GeoNova Capital's investment remain subject to negotiation and execution of definitive documentation and satisfaction of certain conditions to closing.

The companies plan to roll out NovaGen Health Networks in two phases. Phase 1, beginning in the fourth quarter of 2026, will provide a private household health hub with a digital twin for every family member and a patient-controlled health records wallet. The hub will integrate health records, wearable telemetry and longitudinal biological measurements. Built on VeeaONE, the hub processes sensitive data locally and supports AI wellness companions, medication reminders and patient-authorized provider sharing. Plans include personal cell banking and consented research participation, subject to applicable regulatory requirements.

Phase 2 will add clinician-supervised diagnostics and therapy pathways as clinical validation and regulatory authorizations permit. The network will combine digital twins and medical records with cellular data from a small skin biopsy used to initiate the ARC Prometheus process. This biopsy provides a patient's own fibroblasts for cellular reprogramming, rejuvenation, cell banking and potential future autologous therapies. Telomere length, DNA-methylation age and additional biomarkers will be assessed to support clinician evaluation of therapy candidates and treatment monitoring. Validated AI tools will support clinician-reviewed decisions and referrals to authorized treatment centers.

Diederik van der Reijt, CEO of NovaGen Group, said: "NovaGen is a regenerative medicine platform with proprietary autologous rejuvenated fibroblast stem cell technology and a growing network of associated clinics. This agreement with Veea extends our reach to individuals long before they walk into a clinic. NovaGen Health Networks creates a pathway to identify and evaluate potential candidates for our therapies, allowing that relationship to begin earlier and continue through assessment, treatment and follow-up, including the creation of each patient's own digital twin."

Allen Salmasi, Chairman and CEO of Veea, stated: "NovaGen Health Networks demonstrates the power of AI at the edge, bringing Veea's connectivity, computing, cybersecurity, storage and AI capabilities together in one global network, putting intelligence where care happens while giving people far greater control over their most personal information."

Patient privacy and data sovereignty are central to the network's design. Health records remain encrypted at source and off the blockchain; the blockchain ledger records only permissions, document fingerprints and access events. Patients authorize specific recipients, categories of information and access periods and may revoke access at any time. Cloud services use pseudonymous digital twins, with re-identification controlled through protected keys and authorized consent. Veea's cybersecurity architecture incorporates Zero Trust Network Access, network slicing, micro-segmentation and AI-driven anomaly detection to protect the network end-to-end.

Robert Hamilton, Managing Partner for Capital Markets at GeoNova Capital, said: "GeoNova's US$10 million commitment reflects our conviction in NovaGen's strategy and the scale of the opportunity. As corporate adviser and cornerstone institutional investor, our role is to support NovaGen with institutional capital, capital-markets discipline and strategic execution as it advances toward the U.S. public markets."

Veea Inc., founded in 2014 and headquartered in New York City, is a global leader in edge solutions and infrastructure listed on NASDAQ. Veea enables enterprises, service providers and public sector organizations to deploy AI-powered applications at the edge. The VeeaONE platform integrates connectivity, computing, cybersecurity and storage into a unified hyperconverged network solution from edge to cloud. Veea holds more than 123 patents across related technology domains and has been recognized by Gartner for its innovations in edge computing.

NovaGen Group has developed a personalized regenerative medicine and longevity platform integrating ARC Prometheus cellular reprogramming and rejuvenation technology, biological assessment, cell banking, clinical services and digital health. Its strategy connects research and clinical development with a growing network of care locations and partners to support more personalized approaches to health and aging.

GeoNova Capital is a UAE-based investment and capital-markets firm focused on event-driven investing, structured finance, special situations and public-market transactions.